VTRS - Earnings announcements

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in JapanContinues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026Reaffirms 2026 Financial Guidance [1]PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced its fi

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFOPITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition."We thank Doretta for her significant contributions, which have helped prepare the Company

PITTSBURGH, April 13, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the

Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four

PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Co

PITTSBURGH, Oct. 1, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healt

Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global BusinessPositive Results From Five Phase 3 Data Readouts This Year Reinforce Continued Momentum of Late-Stage Pipeline Returns More Than $630 Million of Capital to Shareholders Year-to-Date Including $350 Million in Share BuybacksReiterates 2025 Financial Guidance Ranges Across all Metrics and Expects to be in the Top Half of the Range for Total Revenues and Adjusted EPS [1]PITTSBURGH, Aug. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported strong second quarter 2025 financial results and reiterated its 2025 financial guidance ranges across all metri

PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br

Delivers Total Revenues in Line With Expectations Demonstrating Strength of the Base BusinessMakes Significant Pipeline Progress With Three Positive Phase 3 Data Readouts Returns More Than $450 Million in Capital to Shareholders Year-to-Date and Reaffirms 2025 Capital Allocation Priorities PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1]. Executive Commentary "2025 is off to a good start as we continue to focus on executing our strategic priorities," said Scott A. Smith, CEO, Viatris. "Our growing pipeline, capital discipline, operational execution, and

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthc

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ --  Meets 2024 Guidance for Total Revenues, Adjusted EBITDA and Adjusted EPS; Exceeds 2024 Guidance for Free Cash Flow [1]Reports 2024 Total Revenues of $14.7 Billion, U.S. GAAP Net Loss of $(634) Million, Adjusted EBITDA of $4.7 Billion, U.S. GAAP Diluted EPS Loss of $(0.53) per Share, Adjusted EPS of $2.65 per Share, U.S. GAAP Net Cash Provided by Operating Activities of $2.3 Billion, and Free Cash Flow of $2.0 Billion Including ~$650 Million of Transaction-Related CostsDelivers Strong New Product Revenues of $582 Million in 2024Returns $825 Million in Capital to Shareholders and Repays $3.7 Billion of Debt in 2024An

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report financial results for the fourth quarter and full year 2024 on Thursday, February 27, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more ho

PITTSBURGH, Nov. 7, 2024 /PRNewswire/ --  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~3% on a Divestiture-Adjusted Basis Demonstrate Strength of Company's Base Business[1]  Strong New Product Revenues of $133 Million Drove Growth Across Segments U.S. GAAP Net Earnings were $95 Million; Adjusted EBITDA Grew ~4% to $1.3 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was $0.08 per Share; Adjusted EPS Grew ~6% to $0.75 per Share on a Divestiture-Adjusted Basis[2]  Repaid ~$1.9 Billion of Debt, Expects to Achieve its Long-Term Gross Leverage Target of ~3.0x by end of the Year[3] Entered into Exclusive Licensing Agreement for

PITTSBURGH, Sept. 16, 2024  /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the tradit

PITTSBURGH, Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business  Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted Basis[1]Strong New Product Revenues in the Quarter of $210 Million Drove Growth Across SegmentsU.S. GAAP Net Loss was $326 Million; Adjusted EBITDA Grew ~2% to $1.2 Billion on a Divestiture-Adjusted Basis; U.S. GAAP Diluted EPS was a Loss of $0.27 per Share; Adjusted EPS Grew ~3% to $0.69 per Share on a Divestiture-Adjusted Basis[2]Completion of Divestitures Marks Inflection Point in Company's Move Towards Accelerated Growth and Shareholder ReturnRaises 2024 F

PITTSBURGH, June 7, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditiona

FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™," said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. "We have been engaged in productive dialogue with the U.S. Food and Drug Administration (FDA) with respect to our submitted Special Protocol Assessmen

PITTSBURGH, May 9, 2024 /PRNewswire/ --  Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million Closes Idorsia Transaction, Expanding Portfolio of Innovative Assets Closes Women's Healthcare Business Divestiture Reaffirms 2024 Financial Guidance After Adjusting the Ranges Solely to Reflect t

PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional

PITTSBURGH, Feb. 28, 2024 /PRNewswire/ -- Meets 2023 Guidance for Total Revenues, Adjusted EBITDA and Free Cash Flow[1]  Reports 2023 Total Revenues of $15.4 Billion, U.S. GAAP Net Earnings of $54.7 Million, Adjusted EBITDA of $5.1 Billion, U.S. GAAP Net Cash Provided by Operating Activities of $2.8 Billion and Free Cash Flow of $2.4 Billion  Reports Third Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis in 2023 and Expects to see Continued Growth in 2024[2]  Immediately Adds Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential, Through Global Research and Development Collaboration With Idorsia; Announces R&D Event to be Held

PITTSBURGH, Oct. 10, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its third quarter 2023 financial results on Tuesday, November 7 after the close of the U.S. financial markets. Chief Executive Officer Scott A. Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 5:00 p.m. ET on November 7 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.274.8461 or 203.518.9783 for international callers (Conference ID: VTRSQ323). A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ: VTRS) is a glo

Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the QuarterStrong Results Signal Expected Beginning of Growth JourneyReaffirms that Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow Expected to be at Midpoint of 2023 Guidance Ranges[1] Pays Down $727 Million of Debt Year to DateRemains on Track to Announce Planned Divestitures in 2023Board of Directors Declares Quarterly Dividend of $0.12 per SharePITTSBURGH, Aug. 7, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today reported another strong quarter of oper

PITTSBURGH, June 28, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to report its second quarter 2023 financial results on Monday, August 7 before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on August 7 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800-274-8461 or 203-518-9783 for international callers (Conference ID: VTRSQ223).  A replay of the webcast also will be available on the website. About ViatrisViatris Inc. (NASDAQ:VTRS) is a global he

Reports Total Revenues of $3.73 billion; U.S. GAAP Net Earnings of $225 million; Adjusted EBITDA of $1.34 billion; U.S. GAAP Net Cash Provided by Operating Activities of $971 million; and Free Cash Flow of $923 million for the QuarterExpects Full-Year Total Revenues, Adjusted EBITDA and Free Cash Flow to be at Midpoint of 2023 Guidance Ranges[1] Reaffirms 2024 Phase 2 Outlook from November 7 Strategic UpdateReturns Approximately $400 million of Capital to Shareholders in First Quarter Through Dividends and Share RepurchasesPays Down Debt of $546 million in First QuarterBoard of Directors Declares Quarterly Dividend of $0.12 per SharePITTSBURGH, May 8, 2023 /PRNewswire/ -- Viatris Inc. (NASDA

PITTSBURGH, April 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets. Chief Executive Officer Scott Smith, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on May 8 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800-579-2543 or 785-424-1789 for international callers (Conference ID: VTRSQ123).  A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare

Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis; $10 Million Milestone Linked to Approval Oral APX3330 Achieved Statistical Significance on a Potential Registration Endpoint for Diabetic Retinopathy in ZETA-1 Trial; End-of-Phase 2 FDA Meeting Planned FARMINGTON HILLS, Mich., March 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatm

Smith, a seasoned senior healthcare executive, will lead the company's previously announced Phase 2 strategy and execution Board of Directors thanks Michael Goettler, who will support a smooth transition prior to his departure PITTSBURGH, Feb. 27, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that as it prepares to enter Phase 2 of its previously announced strategic plan in 2024, Scott A. Smith has been appointed by its Board of Directors to lead the execution of that plan as Viatris' new Chief Executive Officer, effective April 1, 2023. In the interim, current CEO Michael Goettler will be working closely with Smith to support a smooth transit

PITTSBURGH, Feb. 27, 2023 /PRNewswire/ --  Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quarter Impact of the Biosimilars Transaction and Acquired IPR&D2023 Guidance Midpoint Reflects Revenue Growth Over 2022, Excluding Full-Year Impact of BiosimilarsReaffirms 2024 Phase 2 Outlook from November 7 Strategic UpdateCompany Increases Return of Capital to Shareholders by Completing $250 Million in Share RepurchasesBoard of Directors Approves 2023 Dividend Policy of Forty-Eight Cents ($0.48) per Share and Declares First Quarter Dividend of Twelve Cents ($0.12) per SharePaid Down Debt of Approximately $3.3 Billion in 2022, Retiring $5.4

PITTSBURGH, Feb. 15, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to report its fourth quarter and full year 2022 financial results on Monday, February 27 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on February 27 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ422).  A replay of the webcast also will be available on the website. About Viatris  Viatris Inc. (NAS

TYRVAYA® (Varenicline Solution) Nasal Spray Achieved Net Product Revenue of $5.6 Million in Q3'22Approximately 34,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Approximately 6,100 Unique Eye Care ProfessionalsNovember 1, 2022 Marked the First Anniversary of the Commercial Launch of TYRVAYA, with Over 97,000 Prescriptions Written as of October 21, 2022Expanded Patient Access and Commercial Coverage for TYRVAYA, with Up to Approximately 117 Million Lives Covered to DateOyster Point Pharma to be Acquired by Viatris, with the Transaction Expected to Close During Q1'23Enrollment Completed in the OLYMPIA Phase 2 Clinical Trial for Stage 1 Neurotrophic Keratopat

Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties Strengthened Financial Position Supports Operations and APX3330 Program into 2025 Conference Call Tomorrow November 8, 2022 at 8:30 AM ET FARMINGTON HILLS, Mich., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP) today announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. (Famy) for the development and commercialization of Nyxol across three indications in US, Europe, Japan, India, China and other global markets. In connection with its separately announced transaction with Famy, Viatris

Expects Biocon Biologics Transaction to Close ShortlyIntends to Begin Executing on Stock Repurchase Program  Enters Agreements to Acquire Oyster Point Pharma and Famy Life Sciences for Aggregate of $700-$750 Million in Cash; Expects to Close in Q1 2023Expects Combination of Acquisitions and Share Repurchases to be Accretive to Adjusted EPS in 2023 on a Standalone BasisAnticipates Acquisitions Will Have the Potential to Add at Least $1 Billion in Net Sales and at Least $500 Million in Adjusted EBITDA by 2028Reaffirms Total Pre-Tax Proceeds Expected from Biocon Transaction and Certain Non-Core Asset Divestitures to be up to Approximately $9 Billion Provides Financial Targets for 2024 to 2028,

Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (NASDAQ:OYST), ("Oyster Point Pharma"), today announced that it has entered into a definitive agreement under which Viatris Inc. (NASDAQ:VTRS), a global healthcare company, would acquire Oyster Point Pharma, a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Viatris intends to acquire Oyster Point Pharma as the foundation of its new ophthalmolo

Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange Headwinds and Absorbing Inflation Impact to DateReports Total Revenues of $4.08 billion; U.S. GAAP Net Earnings of $354 million; Adjusted EBITDA of $1.50 billion; U.S. GAAP Net Cash Provided by Operating Activities of $869 million; and Free Cash Flow of $765 millionStrong Year-to-Date Cash Flow; Approximately $2.81 billion of U.S. GAAP Net Cash Provided by Operating Activities and Approximately $2.56 billion in Free Cash FlowMeets Annual Target of Paying Down Approximately $2.1 billion of Debt Year to Date, One Quarter Ahead of ScheduleBoar

Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow of $719 MillionStrong First Half 2022 Cash Flow; Approximately $1.9 Billion of U.S. GAAP Net Cash Provided by Operating Activities and Approximately $1.8 Billion in Free Cash FlowReaffirms Adjusted EBITDA and Free Cash Flow Guidance Ranges[1] Despite Foreign Exchange Headwinds; Revises Total Revenues Guidance Range Solely to Reflect the Incremental Impact of Foreign ExchangeBoard of Directors Declares Quarterly Dividend of $0.12 Per SharePays Down Approximately $1.5 Billion of Debt in the Fir

PITTSBURGH, July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on August 8 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ222). A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global

PITTSBURGH, May 9, 2022 /PRNewswire/ -- First-Quarter 2022 Results Reflect Strong Operational Start to the YearTotal Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 millionAdjusted EBITDA was $1.59 billionU.S. GAAP Net Cash Provided by Operating Activities was $1.14 billionFree Cash Flow was $1.07 billionAchieves Approximately $120 million in New Product Revenue, on Track for 2022 Target of $600 millionConfirms Biocon Biologics Transaction on Track for Second Half 2022 CloseAnnounces Board of Directors Declares Quarterly Dividend of Twelve Cents ($0.12) per Share Pays Down Approximately $840 million of Debt, on Track for 2022 Target of Approximately $2 billion, and Maintains C

PITTSBURGH, April 8, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its first quarter 2022 financial results on Monday, May 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. EDT on May 9 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ122). A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a new kind of

PITTSBURGH, Nov. 8, 2021 /PRNewswire/ -- Reports Third Quarter 2021 Financial Results: Total Revenues of $4.54 billion; U.S. GAAP Net Earnings of $312 million; Adjusted EBITDA of $1.70 billion; U.S. GAAP Net Cash Provided by Operating Activities of $1.09 billion; and Free Cash Flow of $965 millionRaises 2021 Financial Guidance (1): Total Revenues Guidance Range to $17.70 billion to $17.90 billion, from $17.50 billion to $17.90 billion; Adjusted EBITDA Guidance Range to $6.30 billion to $6.50 billion, from $6.15 billion to $6.45 billion; and Free Cash Flow Guidance Range to $2.40 billion to $2.60 billion, from $2.20 billion to $2.40 billionReturned $266 million to shareholders year to date vi

PITTSBURGH, Oct. 13, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) plans to release its third quarter 2021 financial results on Monday, Nov. 8, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik and Chief Financial Officer Sanjeev Narula also will host a webcast at 10 a.m. ET on Nov. 8 to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 866.342.8591 or 203.518.9713 for international callers (Conference ID: VTRSQ321).  A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a new kind

PITTSBURGH, Aug. 9, 2021 /PRNewswire/ --  Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion, U.S. GAAP Net Loss of $279 million, Adjusted EBITDA of $1.68 billion, U.S. GAAP Net Cash Provided by Operating Activities of $559 million, Free Cash Flow of $470 million Updates 2021 Financial Guidance (1) - Raises Total Revenues Guidance Range to $17.5 billion to $17.9 billion from $17.2 billion to $17.8 billion, Raises Adjusted EBITDA Guidance Range to $6.15 billion to $6.45 billion from $6.0 billion to $6.4 billion, Raises Free Cash Flow Guidance Range to $2.2 billion to $2.4 billion from $2.0 billion to $2.3 billion Announces Board of Directors Declares Quarterl